StockNews.com lowered shares of iCAD (NASDAQ:ICAD - Free Report) from a hold rating to a sell rating in a report released on Tuesday morning.
iCAD Stock Up 6.7 %
Shares of ICAD stock traded up $0.14 on Tuesday, hitting $2.23. The company had a trading volume of 274,829 shares, compared to its average volume of 252,369. The firm has a market cap of $59.18 million, a P/E ratio of -17.15 and a beta of 1.95. The company has a 50-day moving average price of $2.65 and a 200-day moving average price of $2.06. iCAD has a twelve month low of $1.18 and a twelve month high of $3.78.
iCAD (NASDAQ:ICAD - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The technology company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.02. The business had revenue of $5.41 million during the quarter, compared to analysts' expectations of $4.72 million. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%.
Hedge Funds Weigh In On iCAD
Large investors have recently bought and sold shares of the business. waypoint wealth counsel raised its holdings in iCAD by 44.0% in the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company's stock worth $26,000 after purchasing an additional 4,400 shares during the period. Thompson Davis & CO. Inc. acquired a new position in iCAD in the 4th quarter worth about $31,000. PKS Advisory Services LLC acquired a new position in iCAD in the 4th quarter worth about $53,000. Wells Fargo & Company MN raised its holdings in iCAD by 51.3% in the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company's stock worth $72,000 after purchasing an additional 13,402 shares during the period. Finally, Integrated Wealth Concepts LLC acquired a new position in iCAD in the 4th quarter worth about $92,000. Institutional investors and hedge funds own 24.61% of the company's stock.
iCAD Company Profile
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Stories
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
